ArticleStem cells translational medicine2019
Corneal Wound Healing Effects of Mesenchymal Stem Cell Secretome Delivered Within a Viscoelastic Gel Carrier.
Article in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05204329 (Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease), which is not on this map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Who cites it
66 citing papers in PubMed, 117 citations in OpenAlex.
- RNA delivery to the corneal endothelium using charge-altering releasable transporters.Science advances · 2026Article
- Effects of secretome derived from resveratrol treated mesenchymal stem cell on cornea wound: an organ culture study.Scientific reports · 2026Article
- Repair of Corneal Epithelial Defects.Progress in molecular and subcellular biology · 2026Review
- Nanotechnology-Based Treatment for Ophthalmic Diseases.International journal of nanomedicine · 2026Review
- Engineering a functionality-integrated artificial cornea stromal Substitute: Janus bio-adhesive implant with a collagen-based multi-scale biomimetic skeleton.Bioactive materials · 2025Article
- In situ UNIversal Orthogonal Network (UNION) bioink deposition for direct delivery of corneal stromal stem cells to corneal wounds.Bioactive materials · 2025Article
- Single-Atom Colloidal Nanorobotics Enhanced Stem Cell Therapy for Corneal Injury Repair.ACS nano · 2025Article
- Emerging Treatments for Persistent Corneal Epithelial Defects.Vision (Basel, Switzerland) · 2025Review
- Safety and Efficacy of a Mesenchymal Stem Cell Secretome Therapy (KPI-012) for Persistent Corneal Epithelial Defects: A Phase 1b Trial.Current therapeutic research, clinical and experimental · 2025Article
- Extracellular Vesicles for Disease Treatment.International journal of nanomedicine · 2025Review
- Corneal Treatment, Repair, and Regeneration: Exosomes at Rescue.Pharmaceutics · 2024Review
- Equine Corneal Wound Healing Using Mesenchymal Stem Cell Secretome: Case Report.Animals : an open access journal from MDPI · 2024Article
- Mitochondria Transplantation Promotes Corneal Epithelial Wound Healing.Investigative ophthalmology & visual science · 2024Article
- Bone marrow mesenchymal stem cell-derived extracellular vesicles promote corneal epithelial repair and suppress apoptosis via modulation of Caspase-3 in vitro.FEBS open bio · 2024Article
- Human mesenchymal stem cell secretomes: Factors affecting profiling and challenges in clinical application.Cell and tissue research · 2024Review
- Advances in extracellular vesicle functionalization strategies for tissue regeneration.Bioactive materials · 2023Review
- MiRNA 24-3p-rich exosomes functionalized DEGMA-modified hyaluronic acid hydrogels for corneal epithelial healing.Bioactive materials · 2023Article
- Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders.International journal of molecular sciences · 2023Review
- Wound-Healing Effects of Mesenchymal Stromal Cell Secretome in the Cornea and the Role of Exosomes.Pharmaceutics · 2023Article
- Stem Cell's Secretome Delivery Systems.Advanced pharmaceutical bulletin · 2023Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Severe corneal injuries often result in permanent vision loss and remain a clinical challenge. Human bone marrow-derived mesenchymal stem cells (MSCs) and their secreted factors (secretome) have been studied for their antiscarring, anti-inflammatory, and antiangiogeneic properties. We aimed to deliver lyophilized MSC secretome (MSC-S) within a viscoelastic gel composed of hyaluronic acid (HA) and chondroitin sulfate (CS) as a way to enhance corneal re-epithelialization and reduce complications after mechanical and chemical injuries of the cornea. We hypothesized that delivering MSC-S within HA/CS would have improved wound healing effects compared the with either MSC-S or HA/CS alone. The results showed that a once-daily application of MSC-S in HA/CS enhances epithelial cell proliferation and wound healing after injury to the cornea. It also reduced scar formation, neovascularization, and hemorrhage after alkaline corneal burns. We found that combining MSC-S and HA/CS increased the expression of CD44 receptors colocalized with HA, suggesting that the observed therapeutic effects between the MSC-S and HA/CS are in part mediated by CD44 receptor upregulation and activation by HA. The results from this study demonstrate a reproducible and efficient approach for delivering the MSC-S to the ocular surface for treatment of severe corneal injuries. Stem Cells Translational Medicine 2019;8:478-489.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.